Bristol-Myers Squibb (BMY) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Bristol-Myers Squibb (BMY) quarterly earnings & revenue
Bristol-Myers Squibb (BMY) reported revenue of $11.49B for Q1 2026, up 2.6% year-over-year, with net income of $2.68B and diluted EPS of $1.31.
Over the last four reported quarters, Bristol-Myers Squibb generated $48.48B in revenue and $7.28B in net income.
Bristol-Myers Squibb's next earnings report is scheduled for July 30, 2026 before market open; analysts estimate EPS of $1.61.
Bristol-Myers Squibb quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $11.49B | +2.6% | $2.68B | $1.31 |
| Q4 2025 | $12.50B | +1.3% | $1.09B | $0.53 |
| Q3 2025 | $12.22B | +2.8% | $2.20B | $1.08 |
| Q2 2025 | $12.27B | +0.6% | $1.31B | $0.64 |
| Q1 2025 | $11.20B | -5.6% | $2.46B | $1.20 |
| Q4 2024 | $12.34B | +7.5% | $72.00M | $0.04 |
| Q3 2024 | $11.89B | +8.4% | $1.21B | $0.60 |
| Q2 2024 | $12.20B | +8.7% | $1.68B | $0.83 |
Bristol-Myers Squibb (BMY) — frequently asked questions
When does Bristol-Myers Squibb (BMY) report earnings next?
Bristol-Myers Squibb is expected to report earnings on July 30, 2026 before market open. Analysts estimate EPS of $1.61.
What was BMY's revenue last quarter?
Bristol-Myers Squibb reported revenue of $11.49B in Q1 2026, up 2.6% from the same quarter a year earlier.
What was BMY's EPS last quarter?
Bristol-Myers Squibb reported diluted EPS of $1.31 in Q1 2026.
Is Bristol-Myers Squibb profitable?
Bristol-Myers Squibb is currently profitable, with $7.28B in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)